| Reagan-Udall Foundation

Read more about Luxa Biotechnology LLC

Read more about Pharming Group NV

Read more about The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

Read more about Opus Genetics, Inc.

Read more about Dissecting Human Immune Responses to Infection with Influenza or SARS-CoV-2

Read more about The Effect of the Role Performance Strengthening Program on the Adaptive Performance and Competence of Nurses

Read more about Cognitive-Sensorimotor Function in Long-COVID

Read more about COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus

In anticipation of the 2025 Strategic Agenda, the Reagan-Udall Foundation and the FDA co-hosted a stakeholder meeting where the FDA received input on what the Hub should prioritize. Dr. Flores represented BIO in the October 2024 meeting.

Coverage

Read more about Bio.News: BIO celebrates release of FDA Rare Disease Innovation Hub 2025 strategic plan

Read more about EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Subscribe for updates from the Reagan-Udall Foundation for the FDA